Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) play a dominant role in the treatment of non-small cell lung cancer (NSCLC); however, to date, targeted treatment options have not been identified for patients with EGFR exon 20 insertion (ex20ins) mutations. Almoner...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruilin, Yu, Sheng, Yu, Limeng, Zhao, Jiuzhou, Jiao, Shuyue, Wang, Qiming, Wu, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273656/
https://www.ncbi.nlm.nih.gov/pubmed/35836508
http://dx.doi.org/10.21037/tcr-21-2728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273656/
https://www.ncbi.nlm.nih.gov/pubmed/35836508
http://dx.doi.org/10.21037/tcr-21-2728

Ejemplares similares